Aileron Therapeutics. has filed a patent for compositions containing modified caveolin-1 peptides for treating lung infections and lung fibrosis. The claim involves a method of treating fibrosis by administering a specific peptide sequence. GlobalData’s report on Aileron Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Aileron Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Aileron Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Aileron Therapeutics's grant share as of January 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of lung fibrosis using modified cav-1 peptides

Source: United States Patent and Trademark Office (USPTO). Credit: Aileron Therapeutics Inc

A patent application (Publication Number: US20240018186A1) discloses a method for treating or preventing fibrosis in a subject by administering a pharmaceutical composition containing a specific peptide sequence. The peptide sequence, Ac-aaEGKASFTTFTVTKGSaa-NH2 (SEQ ID NO: 8), is administered in an effective amount to the subject. The pharmaceutical composition may include a pharmaceutically acceptable carrier and can be formulated for various routes of administration such as oral, intravenous, topical, or inhalational. Additionally, the composition can be administered systemically or locally to diseased tissue, with options for single or multiple doses at varying frequencies.

Furthermore, the method allows for the administration of the pharmaceutical composition in combination with other therapeutics such as non-steroidal anti-inflammatory drugs, steroids, or anti-fibrotic agents like pirfenidone. The fibrosis conditions that can be targeted include kidney fibrosis, liver fibrosis, heart fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, acute or chronic lung injury-induced fibrosis, and cystic fibrosis. The administration of the pharmaceutical composition is also shown to increase the viability of epithelial cells, particularly lung epithelial cells, and modulate the expression of smooth muscle actin in the subject, indicating potential therapeutic benefits in managing fibrotic conditions.

To know more about GlobalData’s detailed insights on Aileron Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies